In last trading session, Arcus Biosciences Inc (NYSE:RCUS) saw 0.54 million shares changing hands with its beta currently measuring 1.45. Company’s recent per share price level of $9.34 trading at -$0.2 or -2.10% at ring of the bell on the day assigns it a market valuation of $988.56M. That closing price of RCUS’s stock is at a discount of -105.35% from its 52-week high price of $19.18 and is indicating a premium of 3.53% from its 52-week low price of $9.01. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.99 million shares which gives us an average trading volume of 922.09K if we extend that period to 3-months.

For Arcus Biosciences Inc (RCUS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.38. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.01 in the current quarter.

Arcus Biosciences Inc (NYSE:RCUS) trade information

Upright in the red during last session for losing -2.10%, in the last five days RCUS remained trading in the red while hitting it’s week-highest on Tuesday, 03/11/25 when the stock touched $9.34 price level, adding 6.88% to its value on the day. Arcus Biosciences Inc’s shares saw a change of -37.27% in year-to-date performance and have moved -2.51% in past 5-day. Arcus Biosciences Inc (NYSE:RCUS) showed a performance of -22.17% in past 30-days. Number of shares sold short was 6.88 million shares which calculate 5.86 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 32 to the stock, which implies a rise of 70.81% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 46. It follows that stock’s current price would drop -114.13% in reaching the projected high whereas dropping to the targeted low would mean a loss of -114.13% for stock’s current value.

Arcus Biosciences Inc (RCUS) estimates and forecasts

This year revenue growth is estimated to fall -40.13% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 38.61M for the same. And 8 analysts are in estimates of company making revenue of 37.36M in the next quarter. Company posted 145M and 39M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -10.20% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -31.67% while estimates for its earnings growth in next 5 years are of -5.81%.

Arcus Biosciences Inc (NYSE:RCUS)’s Major holders

Insiders are in possession of 5.52% of company’s total shares while institution are holding 83.48 percent of that, with stock having share float percentage of 88.36%. Investors also watch the number of corporate investors in a company very closely, which is 83.48% institutions for Arcus Biosciences Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at RCUS for having 9.76 million shares of worth $148.69 million. And as of 2024-06-30, it was holding 11.3261 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 5.26 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.099 of outstanding shares, having a total worth of $80.07 million.

On the other hand, iShares Core S&P Smallcap ETF and Fidelity Select Portfolios – Biotechnology are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 3.47 shares of worth $32.41 million or 3.30% of the total outstanding shares. The later fund manager was in possession of 1.74 shares on Dec 31, 2024 , making its stake of worth around $16.27 million in the company or a holder of 1.66% of company’s stock.